Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Mayer

Showing results (551-560 of 703) with videos related to

Pageof 71
Sort By:
Neurology|March 13, 2024
CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain InjuryGe Li, Jeffrey Iliff, Jane Shofer, et al.
The New England Journal of Medicine|October 9, 1997
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study GroupS R Targan, S B Hanauer, S J van Deventer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Congestive heart failure risk in patients with breast cancer treated with bevacizumabToni K Choueiri, Erica L Mayer, Youjin Je, et al.
Archives of Environmental Contamination and Toxicology|March 8, 2005
Assessing contaminant sensitivity of endangered and threatened aquatic species: part III. Effluent toxicity testsF J Dwyer, D K Hardesty, C E Henke, et al.
Circulation|November 15, 1995
Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery diseaseK Robinson, E L Mayer, D P Miller, et al.
Annals of Surgical Oncology|September 5, 2023
Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical TrialCharity C Glass, Robert M Pride, Rachel A Freedman, et al.
Breast Cancer Research and Treatment|August 4, 2025
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trialKate Lloyd, Lisa A Newman, Charity Glass, et al.
The Oncologist|December 20, 2024
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancerShadab A Rahman, Hanneke Poort, Deborah Schrag, et al.
The American Journal of Gastroenterology|April 24, 2001
The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset diseaseP N Akolkar, B Gulwani-Akolkar, X Y Lin, et al.
Neurology|August 20, 2017
Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adultsGe Li, Cynthia L Mayer, Daniel Morelli, et al.
Pageof 71

Showing results (551-560 of 703) with videos related to

Sort By:
Pageof 71
Neurology|March 13, 2024
CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain InjuryGe Li, Jeffrey Iliff, Jane Shofer, et al.
The New England Journal of Medicine|October 9, 1997
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study GroupS R Targan, S B Hanauer, S J van Deventer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Congestive heart failure risk in patients with breast cancer treated with bevacizumabToni K Choueiri, Erica L Mayer, Youjin Je, et al.
Archives of Environmental Contamination and Toxicology|March 8, 2005
Assessing contaminant sensitivity of endangered and threatened aquatic species: part III. Effluent toxicity testsF J Dwyer, D K Hardesty, C E Henke, et al.
Circulation|November 15, 1995
Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery diseaseK Robinson, E L Mayer, D P Miller, et al.
Annals of Surgical Oncology|September 5, 2023
Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical TrialCharity C Glass, Robert M Pride, Rachel A Freedman, et al.
Breast Cancer Research and Treatment|August 4, 2025
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trialKate Lloyd, Lisa A Newman, Charity Glass, et al.
The Oncologist|December 20, 2024
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancerShadab A Rahman, Hanneke Poort, Deborah Schrag, et al.
The American Journal of Gastroenterology|April 24, 2001
The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset diseaseP N Akolkar, B Gulwani-Akolkar, X Y Lin, et al.
Neurology|August 20, 2017
Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adultsGe Li, Cynthia L Mayer, Daniel Morelli, et al.
Pageof 71